Innovative approaches to diagnostics, treatment, and patient care are pivotal as we aim to advance and develop new vaccines and therapies. By building on past knowledge with innovations, the discovery phase enables us to optimize research and clinical trials to implement new strategies, with the goal of furthering advancements in healthcare.

In this episode, we had a short, one-on-one conversation with Kimberley Brown, Head of Medical Affairs, Infectious Diseases & Vaccines, Therapeutics at the Janssen Pharmaceutical Companies of Johnson & Johnson, discussing how the discovery process has changed the way we develop critical medical care and the important role this research plays in the development of vaccines and therapeutics.

The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your healthcare provider.

As we approach another fall and winter, which is known to many as flu season, we must recognize that this is respiratory syncytial virus (RSV) season as well. We discuss the diagnosis and treatment of RSV and what you need to know about this highly contagious, yet often less discussed, seasonal respiratory virus (RSV). While RSV often presents with only mild symptoms, it is a leading cause of bronchitis and pneumonia. Older adults and adults with underlying health conditions, as well as young children, are most at risk of serious complications from this highly contagious virus.

There is likely an underestimation of RSV infections worldwide since many who are infected with RSV may not be diagnosed because its symptoms can be difficult to distinguish from the flu, COVID-19, or other respiratory infections. Helping patients, providers, and caregivers to recognize the risks and symptoms associated with RSV has the potential to significantly improve patient health outcomes.

In this episode, we welcome Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, at Janssen, and Patricia A. Stinchfield, R.N., M.S., CPNP, President-Elect of the National Foundation for Infectious Diseases (NFID), as they discuss the impact of the COVID-19 pandemic on the seasonality of RSV, the economic burden of the disease and more.

The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your healthcare provider.

Diversity in healthcare is more important than ever and is associated with better health outcomes and increased access to higher quality medical care for people of color. Yet ensuring the medical pipeline is representative of the diversity of the patient populations served can be challenging.

In this episode, Bryan Baugh, M.D., Global Medical Affairs Leader, GCSO, and Michellene Davis, Esq., CEO, National Medical Fellowships (NMF) discuss the next generation of medical professionals, the challenges and opportunities for creating a diverse and inclusive pipeline, and the benefits that come as a result for patients. 

The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your healthcare provider.